Tirzepatide, fat and lean mass: what did the body-scan study find?

Why does the question matter?

When weight changes, the scale cannot tell which tissues changed. People understandably want to know whether weight loss includes fat, muscle or water, and whether it affects the ability to carry out everyday activities. A body scan can help describe composition, but it cannot by itself answer every question about strength, function or health. Start with fat loss versus weight loss.12

Who was studied?

SURMOUNT-1 was a placebo-controlled tirzepatide trial in adults with obesity or overweight. A body-composition substudy used DXA, a type of low-dose X-ray scan. Of 255 people enrolled in that substudy, the analysis included 160 with scans at baseline and at week 72 or early discontinuation: 124 receiving tirzepatide across pooled study groups and 36 receiving placebo; 73% were women. For three participants, missing week-72 data were estimated using the last available observation. These participants were a selected subset, not every person in the main trial. Eli Lilly funded the study and took part in its design, data collection, analysis, interpretation, reporting and submission.2

What did the scan show?

Both fat mass and lean mass decreased on average, with larger reductions in weight and these components in the tirzepatide group than placebo. The authors estimated that about 75% of weight lost was fat mass and 25% lean mass in each group. These describe group-level estimates in those analysed: they are not a rule that every person loses those proportions. The placebo group also lost weight in the study.

The proportion of weight lost as fat or lean mass was an exploratory analysis performed after the study was designed; it was not the substudy’s primary outcome.2

Is lean mass the same as muscle?

No. Lean or fat-free measurements include tissues and water beyond skeletal muscle, and methods differ. A change in lean mass cannot automatically be labelled the same amount of muscle lost; a scan also does not directly measure strength or daily function. A change in strength would need its own measurement. This study does not establish that an individual will become weaker—or guarantee that they will not.21

What should a reader take from this?

Ask whether a claim refers to total weight, fat mass, lean mass, strength or function, and which population and method were studied. A clinician can discuss an individual’s health, nutrition, activity, medicines and any concern about strength. The tirzepatide profile covers benefits, harms and product distinctions; muscle and exercise provides broader context.2